Eisler Capital Management Ltd. Takes Position in Grifols, S.A. (NASDAQ:GRFS)

Eisler Capital Management Ltd. purchased a new stake in Grifols, S.A. (NASDAQ:GRFS) in the fourth quarter, Holdings Channel reports. The institutional investor purchased 112,700 shares of the biotechnology company’s stock, valued at approximately $846,000.

Other institutional investors also recently modified their holdings of the company. R Squared Ltd purchased a new stake in shares of Grifols in the fourth quarter valued at $28,000. GAMMA Investing LLC raised its position in Grifols by 44.5% during the fourth quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 1,527 shares during the period. Blue Trust Inc. lifted its stake in Grifols by 254.0% in the 4th quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company’s stock worth $52,000 after acquiring an additional 4,970 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in Grifols by 354.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,124 shares of the biotechnology company’s stock worth $60,000 after acquiring an additional 6,335 shares during the period. Finally, First Trust Advisors LP purchased a new position in Grifols during the 4th quarter valued at about $75,000.

Grifols Trading Down 2.1 %

NASDAQ GRFS opened at $7.15 on Friday. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11. Grifols, S.A. has a 1-year low of $5.79 and a 1-year high of $9.96. The firm’s fifty day simple moving average is $7.34 and its 200-day simple moving average is $7.66. The company has a market capitalization of $4.92 billion, a PE ratio of 6.11 and a beta of 0.44.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley initiated coverage on shares of Grifols in a report on Wednesday, February 12th. They set an “overweight” rating for the company.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.